Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?

BACKGROUND. Despite the advent of new treatment strategies, many patients with diffuse large B-cell lymphoma (DLBCL) relapse or die of the disease. Prospective clinical trials have demonstrated that lenalidomide is an effective and safe treatment option, especially for non-germinal center B-cell (no...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncologist
Asıl Yazarlar: Mondello, Patrizia, Steiner, Normann, Willenbacher, Wolfgang, Ferrero, Simone, Ghione, Paola, Marabese, Alessandra, Pitini, Vincenzo, Cuzzocrea, Salvatore, Mian, Michael
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AlphaMed Press 2016
Konular:
Hematologic Malignancies
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5016065/
https://ncbi.nlm.nih.gov/pubmed/27382029
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0103
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller